Mylan N.V. (MYL)
(Delayed Data from NSDQ)
$28.01 USD
+0.33 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $28.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.01 USD
+0.33 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $28.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Mylan (MYL) Down 12.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Mylan N.V. (MYL) a Great Stock for Value Investors?
by Zacks Equity Research
Is Mylan N.V. a great pick from the value investor's perspective right now? Read on to know more.
Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices
by Parth Panchal
A President Donald Trump tweet promising to increase competition and decrease prices in the drug industry sent pharmaceutical stocks falling on Tuesday.
The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi
Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Theravance Biopharma, Inc. (TBPH) reported fourth-quarter 2016 loss of $1.36 per share, much wider than both the Zacks Consensus Estimate of a loss of $1.07 and the year-ago loss of $1.23.
Mylan (MYL) to Post Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Mylan N.V. (MYL) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.
Where Are the Best Buying Opportunities in Stocks Right Now?
by Tracey Ryniec
With stocks hitting new record highs, you might think there???s nothing left to buy. But some of the biggest money managers beg to differ.
Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
by Zacks Equity Research
Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.
CVS Debuts Cheap EpiPen Alternative
by Madeleine Johnson
On Thursday, leading drug store chain CVS Health Corp. (CVS) announced that it is now selling a cheaper alternative to Mylan's (MYL) EpiPen.
Valeant Streamlines Portfolio with Skincare Brands Sale
by Zacks Equity Research
Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it has entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L'Or??al for $1.3 billion in cash.
Valeant to Sell Dendreon Unit to Sanpower for $820 Million
by Zacks Equity Research
Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it will sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower Group Co., Ltd.
Is Valeant (VRX) Fated for Terrible 2017 As Well?
by Zacks Equity Research
Shares of Valeant Pharmaceuticals, Inc. (VRX) slumped 85.3% in 2016, eroding a chunk of shareholders' net worth.
Company News for January 03, 2017
by Zacks Equity Research
Companies In The News are: MYL,JNJ,GPOR,PBR,S,TMUS
Mylan (MYL) Announces Multiple Generic Launches in the U.S.
by Zacks Equity Research
Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.
Mylan/Biocon's Herceptin Biosimilar Phase III Data Published
by Zacks Equity Research
Mylan (MYL) and partner Biocon's biosimilar version of Herceptin phase III data published in JAMA.
Mylan (MYL) Launches Authorized Generic EpiPen at $300
by Zacks Equity Research
Mylan (MYL) announced the launch of the first generic version of its life-saving allergy treatment, EpiPen, at more than 50% discount to the branded product.
Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK
by Zacks Equity Research
Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.
Trump Vows to Slash Drug Prices, Sends Biotech Stocks Lower
by Ryan McQueeney
Shares of the iShares Nasdaq Biotechnology ETF (IBB) are down more than 3.6% in morning trading Wednesday following a new warning from President-elect Donald Trump that he will indeed be targeting high drug prices.
Stock Market News for November 10, 2016
by Zacks Equity Research
Benchmarks finished higher on Wednesday as investors embraced the election of Republican Donald Trump as the president of the United States
Mylan (MYL) Misses Q3 Earnings, Reiterates 2016 EPS Forecast
by Madeleine Johnson
Mylan NV (MYL) just released its third quarter fiscal 2016 financial results, posting earnings of $1.38 per share and revenues of $3.06 billion.
Your Two Minute Earnings Preview for Mylan (MYL) Stock
by Eric Dutram
Drug companies have been under pressure thanks to worries over politics and growth. Can Mylan give investors some much needed optimism when it reports later this week?
The Best Options Trade for Mylan (MYL) Earnings
by David Bartosiak
Join Dave Bartosiak at 1:30pm Central Time on Monday, November 7th, to see his thoughts on Mylan (MYL) before they report earnings with real-time options insight.
Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen
Pricing Issues Continue to Weigh on the Pharma Sector
by Zacks Equity Research
With generics and biosimilars on the rise, many pharma companies are looking towards new products to pick up the pace and make up for lost sales.
Pharma Industry Outlook - November 2016
by Arpita Dutt
It's been a rough year for pharma and biotech stocks, with media and political focus on the high price of drugs, mixed performance results, slower-than-expected new product launches and increasing competition.